Nishida Yohei, Hashimoto Yusuke, Orita Kumi, Nishino Kazuya, Kinoshita Takuya, Iida Ken, Nakamura Hiroaki
Department of Orthopaedic Surgery, Osaka City General Hospital, Osaka, Japan.
Department of Health and Sport Management, Osaka University of Health and Sports Science, Graduate School of Sport and Exercise Science, Osaka, Japan.
Asia Pac J Sports Med Arthrosc Rehabil Technol. 2024 Jul 8;37:27-32. doi: 10.1016/j.asmart.2024.06.003. eCollection 2024 Jul.
BACKGROUND/OBJECTIVE: Cartilage oligomeric matrix protein (COMP) has utility as a diagnostic marker for osteoarthritis (OA). Our previous study revealed that the serum COMP level can be used to detect early cartilage change in non-OA patients with anterior cruciate ligament (ACL)-deficiency. However, there are still no studies on detecting the progression of cartilage degeneration in early OA. The aim of present study was to investigate whether serum COMP can detect the progression of cartilage degeneration after ACL reconstruction in non-OA patients.
Patients without cartilage degeneration of early OA at ACL reconstruction and whose serum COMP levels could be measured were included in the study. Cartilage degeneration of early OA were defined as International Cartilage Repair Society (ICRS) grade 1 to 4 in more than 2 compartments or ICRS grade 2 to 4 in 1 compartment. The patients were divided into two groups: those who had cartilage degeneration of early OA at second-look arthroscopy (cartilage degeneration progression group) and those who did not (non-progression group), and the serum COMP values between the two groups were compared.
Thirty-one patients were included. There were 8 cases (25.8 %) in progression group and 23 cases (74.2 %) in non-progression group. There were significant differences between the two groups regarding age and change in serum COMP level. In terms of the rate of change in COMP, an increase of more than 1.24-fold was the cut-off value for detecting the progression of cartilage degeneration.
In this study, the increase in serum COMP levels was significantly greater in progressed cartilage degeneration group than non-progression group after ACL reconstruction. Longitudinal serum COMP measurement could detect the progression of cartilage degeneration.
Level Ⅲ, retrospective comparative study.
背景/目的：软骨寡聚基质蛋白（COMP）可作为骨关节炎（OA）的诊断标志物。我们之前的研究表明，血清COMP水平可用于检测前交叉韧带（ACL）损伤的非OA患者的早期软骨变化。然而，目前尚无关于检测早期OA软骨退变进展的研究。本研究的目的是探讨血清COMP能否检测非OA患者ACL重建后软骨退变的进展情况。
本研究纳入了ACL重建时无早期OA软骨退变且可测量血清COMP水平的患者。早期OA的软骨退变定义为：超过2个区域的国际软骨修复协会（ICRS）1至4级，或1个区域的ICRS 2至4级。将患者分为两组：二次关节镜检查时有早期OA软骨退变的患者（软骨退变进展组）和无软骨退变的患者（非进展组），比较两组之间的血清COMP值。
共纳入31例患者。进展组8例（25.8%），非进展组23例（74.2%）。两组在年龄和血清COMP水平变化方面存在显著差异。就COMP的变化率而言，增加超过1.24倍是检测软骨退变进展的临界值。
在本研究中，ACL重建后软骨退变进展组的血清COMP水平升高显著高于非进展组。纵向检测血清COMP可检测软骨退变的进展。
Ⅲ级，回顾性比较研究。
